The invention belongs to the field of chemical medicines, and particularly relates to a novel
crystal form of a rerugolil 2-methyltetrahydrofuran solvate, and the novel
crystal form of rerugolil 2-methyltetrahydrofuran is a
crystal form alpha. Compared with an existing crystal form, the crystal form has high
solubility and excellent
powder property, is beneficial to storage and operation in a production process, is low in
impurity content, and is beneficial to purification of a rugolix crude product and feeding in a refining step.